Renal function during rofecoxib therapy in patients with metastatic cancer: retrospective analysis of a prospective phase II trial

BACKGROUND: Angiostatic/antiinflammatory therapy with COX-II inhibitors and pioglitazone seems to be a well tolerated and promising regimen in patients with metastatic cancer. COX-II inhibitors may have less gastrointestinal side effects than conventional non-steroidal antiinflammatory drugs, but th...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinhold, Stephan W, Reichle, Albrecht, Leiminger, Sonja, Bergler, Tobias, Hoffmann, Ute, Krüger, Bernd, Banas, Bernhard, Krämer, Bernhard K
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038926/
https://www.ncbi.nlm.nih.gov/pubmed/21208422
http://dx.doi.org/10.1186/1756-0500-4-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038926/
https://www.ncbi.nlm.nih.gov/pubmed/21208422
http://dx.doi.org/10.1186/1756-0500-4-2

Ejemplares similares